Phase II trial of IPH 2201 combination therapy in patients with platinum resistant ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Feb 2015
Price : $35 *
At a glance
- Drugs Monalizumab (Primary) ; Antineoplastics
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Innate Pharma
- 19 Feb 2015 According to Innate Pharma media release, this trial is expected to begin in 2015.
- 17 Apr 2014 New trial record